Abstract

BackgroundHirano bodies are actin-rich paracrystalline inclusions found in brains of patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and in normal aged individuals. Although studies of post-mortem brain tissue provide clues of etiology, the physiological function of Hirano bodies remains unknown. A cell culture model was utilized to study the interactions of mutant tau proteins, model Hirano bodies, and GSK3β in human astrocytoma cells.ResultsMost tau variants showed co-localization with model Hirano bodies. Cosedimentation assays revealed this interaction may be direct, as recombinant purified forms of tau are all capable of binding F-actin. Model Hirano bodies had no effect or enhanced cell death induced by tau in the absence of amyloid precursor protein intracellular domain (AICD). In the presence of AICD and tau, synergistic cell death was observed in most cases, and model Hirano bodies decreased this synergistic cell death, except for forms of tau that caused significant cell death in the presence of Hirano bodies only. A role for the kinase GSK3β is suggested by the finding that a dominant negative form of GSK3β reduces this synergistic cell death. A subset of Hirano bodies in brain tissue of both Alzheimer’s disease and normal aged individuals was found to contain tau, with some Hirano bodies in Alzheimer’s disease brains containing hyperphosphorylated tau.ConclusionThe results demonstrate a complex interaction between tau and AICD involving activation of GSK3β in promoting cell death, and the ability of Hirano bodies to modulate this process.

Highlights

  • Hirano bodies are actin-rich paracrystalline inclusions found in brains of patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and in normal aged individuals

  • Expression of mutant tau found in FTDP-17 (R5H, G272V, P301L, R406W) has differential effects on cell death when expressed in cell cultures and in various animal models of tauopathy [24,45,46] and these effects may be attributable to the biochemical properties of tau [47,48]

  • Tau, and amyloid precursor protein intracellular domain (AICD) Since previous reports have indicated that model Hirano bodies protected against AICD-induced cell death in the presence of 352WT or 352PHP [44], we investigated whether model Hirano bodies would have an effect on cell death induced by FTDP-17 tau (R5H, G272V, P301L, R406W), or truncated tau (K18 or K18ΔK280) in the presence of AICD

Read more

Summary

Introduction

Hirano bodies are actin-rich paracrystalline inclusions found in brains of patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and in normal aged individuals. In approximately 1% of total AD cases, studies show that neurodegeneration results from mutations in the genes encoding the amyloid precursor protein (APP), presenilin 1 (PSEN1), or PSEN2 [2,3]. Complementary to the amyloid cascade hypothesis was the discovery that mutations in tau cause a familial neurodegenerative disease called frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [13]. This disease and its sporadic (non-familial) counterparts, known as frontotemporal lobar degeneration with taupositive inclusions (FTLD-tau), are characterized pathologically by the formation of neurofibrillary tangles (NFTs) and other neuronal and glial inclusions composed of hyperphosphorylated tau [14]. Significant plaque pathology is often reported in tauopathy patients’ brain tissue [15,16,17,18,19]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call